Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFLY Butterfly Network	$1.43 +1.4%	$1.88	$0.90 ▼ $4.98	$354.95M	2.45	3.84 million shs	3.16 million shs
NPCE NeuroPace	$8.56 -5.2%	$9.91	$5.45 ▼ $18.98	$298.73M	1.89	198,206 shs	285,472 shs
NVNO enVVeno Medical	$4.91 +9.1%	$4.48	$2.03 ▼ $5.70	$86.61M	1.01	146,324 shs	166,361 shs
RXST RxSight	$8.43 +2.6%	$10.34	$6.32 ▼ $58.23	$336.33M	1.16	1.14 million shs	1.14 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFLY Butterfly Network	+1.79%	+7.12%	-20.33%	-39.53%	+53.08%
NPCE NeuroPace	-5.20%	-4.68%	-6.04%	-51.06%	+26.44%
NVNO enVVeno Medical	+9.11%	+5.82%	+14.99%	+35.64%	-5.76%
RXST RxSight	+2.55%	+17.25%	+15.80%	-40.59%	-83.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFLY Butterfly Network	2.5025 of 5 stars	3.4	3.0	1.1	2.5	0.6
NPCE NeuroPace	3.335 of 5 stars	3.5	3.0	3.0	3.3	0.6
NVNO enVVeno Medical	0.806 of 5 stars	0.0	2.0	3.8	0.8	0.6
RXST RxSight	1.4902 of 5 stars	3.0	1.0	1.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFLY Butterfly Network	2.75	Moderate Buy	$3.00	109.78% Upside
NPCE NeuroPace	3.00	Buy	$16.60	93.93% Upside
NVNO enVVeno Medical	0.00	N/A	N/A	N/A
RXST RxSight	1.91	Reduce	$10.00	18.62% Upside

Current Analyst Ratings Breakdown

Latest NVNO, BFLY, RXST, and NPCE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	NPCE NeuroPace	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$17.00 ➝ $15.00
8/8/2025	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
8/8/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.00 ➝ $8.00
8/8/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $11.00
8/4/2025	BFLY Butterfly Network	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Positive ➝ Positive	$2.00
8/1/2025	BFLY Butterfly Network	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/15/2025	RXST RxSight	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $9.00
7/10/2025	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$24.00 ➝ $9.00
7/9/2025	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $9.00
7/9/2025	RXST RxSight	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $10.00
7/9/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $9.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFLY Butterfly Network	$82.06M	4.39	N/A	N/A	$0.92 per share	1.55
NPCE NeuroPace	$79.91M	3.54	N/A	N/A	$0.59 per share	14.51
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	$1.72 per share	N/A
RXST RxSight	$139.93M	2.47	N/A	N/A	$6.79 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFLY Butterfly Network	-$72.49M	-$0.28	N/A	N/A	N/A	-71.79%	-30.53%	-21.80%	N/A
NPCE NeuroPace	-$27.14M	-$0.84	N/A	N/A	N/A	-29.29%	-168.61%	-25.48%	N/A
NVNO enVVeno Medical	-$21.82M	-$1.20	N/A	N/A	N/A	N/A	-57.35%	-53.49%	10/29/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.80	N/A	N/A	N/A	-21.93%	-11.56%	-10.31%	N/A

Latest NVNO, BFLY, RXST, and NPCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	NPCE NeuroPace	-$0.24	-$0.26	-$0.02	-$0.26	$23.08 million	$23.52 million
8/7/2025	Guidance Update	RXST RxSight	-$0.04	-$0.08	-$0.04	-$0.29	$39.78 million	$33.64 million
8/1/2025	Q2 2025	BFLY Butterfly Network	-$0.07	-$0.06	+$0.01	-$0.06	$23.91 million	$23.38 million
7/31/2025	Q2 2025	NVNO enVVeno Medical	-$0.28	-$0.33	-$0.05	-$0.33	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFLY Butterfly Network	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFLY Butterfly Network	N/A	5.68	4.14
NPCE NeuroPace	3.02	5.47	5.70
NVNO enVVeno Medical	N/A	11.81	11.81
RXST RxSight	N/A	13.93	11.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFLY Butterfly Network	37.85%
NPCE NeuroPace	78.83%
NVNO enVVeno Medical	34.71%
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
BFLY Butterfly Network	25.18%
NPCE NeuroPace	20.50%
NVNO enVVeno Medical	16.00%
RXST RxSight	9.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFLY Butterfly Network	460	251.74 million	188.35 million	Optionable
NPCE NeuroPace	170	33.08 million	26.30 million	Optionable
NVNO enVVeno Medical	30	19.25 million	16.17 million	Optionable
RXST RxSight	220	40.92 million	37.00 million	Optionable

NVNO, BFLY, RXST, and NPCE Headlines

Recent News About These Companies

Deadline Alert: RxSight, Inc. (RXST) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

August 15 at 1:08 PM | globenewswire.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of RxSight, Inc. (RXST) Shareholders

August 15 at 9:15 AM | prnewswire.com

Faruqi & Faruqi Reminds RxSight Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - RXST

August 15 at 8:59 AM | prnewswire.com

RXST FRAUD REMINDER: RxSight, Inc. Stock Drop Triggers Securities Fraud Class Action – Contact BFA Law before Imminent September 22 Deadline (NASDAQ:RXST)

August 15 at 8:18 AM | globenewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in RxSight, Inc. Lawsuit – RXST

August 14 at 4:38 PM | globenewswire.com

RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit

August 14 at 4:10 PM | prnewswire.com

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages RxSight, Inc. ...

August 14 at 2:27 PM | gurufocus.com

RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

August 14 at 1:21 PM | gurufocus.com

RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

August 14 at 12:00 PM | prnewswire.com

Class Action Filed Against RxSight, Inc. (RXST) - September 22, 2025 Deadline to Join - Contact ...

August 14 at 9:18 AM | gurufocus.com

Class Action Filed Against RxSight, Inc. (RXST) - September 22, 2025 Deadline to Join - Contact The Gross Law Firm

August 14 at 8:45 AM | prnewswire.com

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of RxSight, Inc.(RXST) Shareholders

August 13 at 4:40 PM | globenewswire.com

RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 13 at 4:00 PM | globenewswire.com

Shareholders who lost money on their RxSight, Inc. (NASDAQ: RXST) Investment Should Contact Wolf Haldenstein Immediately as the Lead Plaintiff Deadline is September 22nd

August 13 at 3:23 PM | globenewswire.com

RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

August 13 at 12:00 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

August 13 at 10:27 AM | globenewswire.com

RXSIGHT STOCK: Lose Money on Your RxSight, Inc. (NASDAQ:RXST) Investment? Contact BFA Law before the September 22 Legal Deadline

August 13 at 8:33 AM | globenewswire.com

RxSight’s Earnings Call: Mixed Results Amid Growth and Challenges

August 13 at 2:54 AM | msn.com

Investors Who Lost Money on RxSight, Inc. (RXST) Should Contact Levi & Korsinsky About Pending Class Action - RXST

August 12, 2025 | theglobeandmail.com

RXST INVESTOR NOTICE: RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

August 12, 2025 | prnewswire.com

RxSight (NASDAQ:RXST) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

August 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVNO, BFLY, RXST, and NPCE Company Descriptions

Butterfly Network NYSE:BFLY

$1.43 +0.02 (+1.43%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$1.43 0.00 (-0.01%)

As of 08/15/2025 07:57 PM Eastern

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

NeuroPace NASDAQ:NPCE

$8.56 -0.47 (-5.20%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.58 +0.02 (+0.23%)

As of 08/15/2025 04:50 PM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

enVVeno Medical NASDAQ:NVNO

$4.91 +0.41 (+9.11%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.87 -0.04 (-0.81%)

As of 08/15/2025 07:47 PM Eastern

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

RxSight NASDAQ:RXST

$8.43 +0.21 (+2.55%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.46 +0.04 (+0.42%)

As of 08/15/2025 07:56 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time